Literature DB >> 7766841

Parvalbumin is a marker of ALS-resistant motor neurons.

J L Elliott1, W D Snider.   

Abstract

The selective vulnerability of limb and bulbar motor neurons is a hallmark of degenerative human motor neuron diseases such as amyotrophic lateral sclerosis (ALS). Currently, there are no known molecular characteristics to distinguish between motor neuron pools which are highly susceptible to degeneration in ALS and those populations which are resistant. Using in situ hybridization on adult rat tissue, we demonstrated that ALS-resistant motor pools robustly express mRNA for the calcium binding protein parvalbumin, while no measurable parvalbumin expression is found in ALS-sensitive motor neuron populations. In contrast, mRNA expression for each of several other calcium binding proteins such as calbindin-D28K, calretinin and calmodulin appears similar in the various motor pools. Thus, parvalbumin represents a biochemical marker of ALS-resistant motor neurons, and may provide insight into the mechanisms of resistance of certain motor neurons to disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7766841     DOI: 10.1097/00001756-199502000-00011

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  28 in total

1.  Calcium dynamics and buffering in oculomotor neurones from mouse that are particularly resistant during amyotrophic lateral sclerosis (ALS)-related motoneurone disease.

Authors:  B K Vanselow; B U Keller
Journal:  J Physiol       Date:  2000-06-01       Impact factor: 5.182

2.  Combinations of AMPA receptor subunit expression in individual cortical neurons correlate with expression of specific calcium-binding proteins.

Authors:  M Kondo; R Sumino; H Okado
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

3.  Marked synergism between mutant SOD1 and glutamate transport inhibition in the induction of motor neuronal degeneration in spinal cord slice cultures.

Authors:  Hong Z Yin; John H Weiss
Journal:  Brain Res       Date:  2012-02-09       Impact factor: 3.252

4.  AMPA exposures induce mitochondrial Ca(2+) overload and ROS generation in spinal motor neurons in vitro.

Authors:  S G Carriedo; S L Sensi; H Z Yin; J H Weiss
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

Review 5.  RNA-binding proteins associated molecular mechanisms of motor neuron degeneration pathogenesis.

Authors:  Anna Y Tang
Journal:  Mol Biotechnol       Date:  2014-09       Impact factor: 2.695

6.  Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms.

Authors:  J Roy; S Minotti; L Dong; D A Figlewicz; H D Durham
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

7.  Adaptive modifications in the calpain/calpastatin system in brain cells after persistent alteration in Ca2+ homeostasis.

Authors:  Roberto Stifanese; Monica Averna; Roberta De Tullio; Marco Pedrazzi; Francesco Beccaria; Franca Salamino; Marco Milanese; Giambattista Bonanno; Sandro Pontremoli; Edon Melloni
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

8.  Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant.

Authors:  T L Williamson; L I Bruijn; Q Zhu; K L Anderson; S D Anderson; J P Julien; D W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

9.  Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase.

Authors:  S Couillard-Després; Q Zhu; P C Wong; D L Price; D W Cleveland; J P Julien
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 10.  Vitamin D as a potential therapy in amyotrophic lateral sclerosis.

Authors:  Alexandro Gianforcaro; Mazen J Hamadeh
Journal:  CNS Neurosci Ther       Date:  2014-02       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.